NCT04200937

Brief Summary

The objective of the It MATTERS registry is to collect Real-World Data (RWD) to monitor the safe and effective use of commercially available Boston Scientific Corporation (BSC) penile prostheses

Trial Health

78
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
67mo left

Started Aug 2021

Longer than P75 for all trials

Geographic Reach
3 countries

25 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Aug 2021Dec 2031

First Submitted

Initial submission to the registry

December 11, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 16, 2019

Completed
1.6 years until next milestone

Study Start

First participant enrolled

August 5, 2021

Completed
9.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2031

Expected
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2031

Last Updated

June 12, 2026

Status Verified

June 1, 2026

Enrollment Period

9.4 years

First QC Date

December 11, 2019

Last Update Submit

June 11, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline to six months in the Erectile Function domain ofthe International Index of Erectile Function (IIEF-EF) questionnaire for Tactra

    The International Index of Erectile Function (IIEF) is a validated, widely used, multidimensional self-report instrument for the evaluation of erectile function. It consists of 15 items that assess sexual function in five domains: erectile function (Q1, 2, 3, 4, 5,15), orgasmic function (Q9,10), sexual desire (Q11,12), intercourse satisfaction (Q 6,7,8) and overall satisfaction (Q 13,14). A score of 0-5 is awarded to each of the 15 questions. The IIEF-15 total score is the sum of the ordinal responses to the 5 domains. The erectile function (EF) domain is the most sensitive domain of the IIEF. IIEF-EF score ranges from 1 to 30 and is derived by scoring 0 (poorest function) to 5 (best function) on each of six questions function (Q1, 2, 3, 4, 5, 15). There are five categories of erectile function based on EF domain score: severe (1-10), moderate (11-16), mild to moderate (17-21), mild (22-25) and no ED (26-30).

    Baseline to 6 months

Secondary Outcomes (3)

  • Change in depressive symptoms and overall sexual function at Post-Surgery, 6 months, 12 months and annually thereafter post device implantation compared to baseline, as measured by the PHQ-9 Depression Questionnaire and the IIEF: Total Score.

    Post-Surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years

  • Change in quality of life at 6 months, 12 months, and 24 months post device implantation compared to baseline as measured by the WPAI:GH Questionnaire.

    6 months, 12 months and 24 months

  • Change in erectile function at post-surgery, 12 months and annually post device implantation compared to baseline, as measured by the International Index of Erectile Function Domain (IIEF).

    Post-Surgery, 12 months and annually thereafter through study completion, an average of 10 years

Other Outcomes (2)

  • Device satisfaction at post-surgery, 6 months, 12 months and annually thereafter measured by the Likert scale.

    Post-surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years

  • Assess for outcomes and adverse events on AMS Tools at Post Procedure.

    Collected only at Post-Procedure

Study Arms (1)

BSC Penile Prothesis Recipients

Men for whom BSC Penile Prothesis is recommended.

Device: Tactra MalleableDevice: Spectra™ Concealable Penile ProthesisDevice: AMS Ambicor™ Inflatable Penile ProsthesisDevice: AMS 700™ Inflatable Penile Prosthesis w/Momentary Squeeze (MS) PumpDevice: AMS 700™ Inflatable Penile Prosthesis w/Tenacio™ Pump

Interventions

The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.

BSC Penile Prothesis Recipients

The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.

BSC Penile Prothesis Recipients

The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.

BSC Penile Prothesis Recipients

The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).

BSC Penile Prothesis Recipients

The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).

BSC Penile Prothesis Recipients

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult males who meet the indications for surgical correction of erectile dysfunction will be enrolled.

You may qualify if:

  • ≥ 18 years of age.
  • Males who are determined to be suitable candidates and scheduled to undergo surgical implantation of a market approved BSC penile prothesis by their physician.
  • Willing and able to complete the informed consent process.
  • Willing and able to comply with the follow-up requirements.

You may not qualify if:

  • Males who are deemed by their physician as not suitable candidates for a penile prosthesis.
  • In the opinion of the investigator, it is not in best interest of the patient or the study for the patient to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (25)

USC Medical Center

Los Angeles, California, 90033, United States

Location

Ronald Reagan UCLA Medical Center

Los Angeles, California, 90095, United States

Location

Tower Urology-Research Facility

Los Angeles, California, 99048, United States

Location

University of Miami Hospital

Miami, Florida, 33136, United States

Location

USF Health South Tampa Center for Advanced Healthcare

Tampa, Florida, 33606, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

SIU School of Medicine

Springfield, Illinois, 62702, United States

Location

Indiana University Medical Center

Indianapolis, Indiana, 46202, United States

Location

Willis-Knighton Medical Center

Bossier City, Louisiana, 71111, United States

Location

Washington University in St. Louis

St Louis, Missouri, 63110, United States

Location

Duke University Medical Center

Raleigh, North Carolina, 27609, United States

Location

W.G. Hefner VA Medical Center

Salisbury, North Carolina, 28144, United States

Location

Wake Forest University

Winston-Salem, North Carolina, 27103, United States

Location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Ohio State University Wexner Medical Center

Columbus, Ohio, 43212, United States

Location

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

Location

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

Houston Methodist Hospital

Houston, Texas, 77030, United States

Location

University of Utah

Salt Lake City, Utah, 84132, United States

Location

University of Washington Medical Center

Seattle, Washington, 98195, United States

Location

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

Peking University First Hospital

Beijing, 100034, China

Location

Shanghai General Hospital

Shanghai, 200080, China

Location

Shanghai Jiaotong University School of Medicine Renji Hospital

Shanghai, 200127, China

Location

Johns Hopkins Aramco Healthcare

Dhahran, 34465, Saudi Arabia

Location

MeSH Terms

Conditions

Erectile Dysfunction

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesSexual Dysfunction, PhysiologicalMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental Disorders

Study Officials

  • Mohit Khera, MD

    Baylor College of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 11, 2019

First Posted

December 16, 2019

Study Start

August 5, 2021

Primary Completion (Estimated)

January 1, 2031

Study Completion (Estimated)

December 1, 2031

Last Updated

June 12, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations